MARKET

NVS

NVS

Novartis
NYSE

Real-time Quotes | Nasdaq Last Sale

83.57
+0.77
+0.93%
Pre Market: 83.28 -0.29 -0.35% 09:25 09/24 EDT
OPEN
83.56
PREV CLOSE
82.80
HIGH
83.98
LOW
83.53
VOLUME
1.53K
TURNOVER
--
52 WEEK HIGH
98.52
52 WEEK LOW
77.04
MARKET CAP
186.92B
P/E (TTM)
21.12
1D
5D
1M
3M
1Y
5Y
Incyte (INCY) Jakafi Wins FDA Approval for Chronic GVHD
Zacks.com · 1d ago
Down More Than 8% in the Past Month, Should You Scoop Up Shares of Merck & Co?
StockNews.com · 1d ago
Green Hygienics Holdings To Raise $100M Via Green Bond Offering
Hemp company Green Hygienics Holdings Inc. (OTCQB: GRYN) is about to secure some $100 million in financing through the offering of a green bond exclusively in Europe.
Benzinga · 1d ago
The Zacks Analyst Blog Highlights: Facebook, Walmart, Novartis, PayPal and Advanced Micro Devices
Zacks.com · 2d ago
Top Research Reports for Facebook, Walmart & Novartis
Zacks.com · 2d ago
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Sept. 20, 2021: PRLB, IRDM, TER, TWLO, SE, SMFR, NVS, INTU, DOCU, AMZN, NVDA
Proto Labs (PRLB) - 33,400 Iridium Communications (IRDM) - 61,565 Teradyne (TER) - 89,816 Twilio (TWLO) - 134,211  Sea (SE) - 162,374  Sema4 Holdings Corp (SMFR)
Benzinga · 2d ago
10 Stocks That Just Received Sell Rating from Analysts
In this article, we discuss the 10 stocks that just received a Sell rating from analysts. If you want to skip our detailed analysis of these stocks, go directly to the 5 Stocks That Just Received Sell Rating from Analysts. The spread of the Delta variant o...
Insider Monkey · 2d ago
Novartis Adds Vision Loss Gene Therapy Program Via Arctos Acquisition
Novartis AG (NYSE: NVS) has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. 
Benzinga · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVS. Analyze the recent business situations of Novartis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVS stock price target is 104.80 with a high estimate of 108.00 and a low estimate of 100.00.
EPS
Institutional Holdings
Institutions: 1.52K
Institutional Holdings: 247.84M
% Owned: 11.08%
Shares Outstanding: 2.24B
TypeInstitutionsShares
Increased
391
7.69M
New
69
4.02M
Decreased
406
12.05M
Sold Out
76
892.34K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.99%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Non-Executive Chairman/Independent Director
Joerg Reinhardt
Chief Executive Officer/Executive Board
Vasant Narasimhan
Non-Executive Vice Chairman/Lead Director/Independent Director
Enrico Vanni
Chief Financial Officer/Executive Board
Harry Kirsch
Chief Human Resource Officer/Executive Board
Steven Baert
Chief Technology Officer/Executive Board
Steffen Lang
Chief Compliance Officer/Chief Risk Officer/Executive Board
Klaus Moosmayer
Executive Board
James Bradner
Executive Board
Shannon Klinger
Executive Board
Richard Saynor
Executive Board
Susanne Schaffert
Executive Board
John Tsai
Executive Board
Marie-France Tschudin
Executive Board
Robert Weltevreden
Secretary
Charlotte Pamer-Wieser
Non-Executive Independent Director
Nancy Andrews
Non-Executive Independent Director
Ton Buechner
Non-Executive Independent Director
Patrice Bula
Non-Executive Independent Director
Srikant Datar
Non-Executive Independent Director
Elizabeth Doherty
Non-Executive Independent Director
Ann Fudge
Non-Executive Independent Director
Bridgette Heller
Non-Executive Independent Director
Simon Moroney
Non-Executive Independent Director
Charles Sawyers
Non-Executive Independent Director
Frans van Houten
Non-Executive Independent Director
Andreas von Planta
Non-Executive Independent Director
William Winters
Declaration Date
Dividend Per Share
Ex-Div Date
01/26/2021
Dividend USD 2.0793972
03/04/2021
01/31/2020
Dividend USD 2.0067876
03/03/2020
--
Dividend USD 1.842184
03/04/2019
--
Dividend USD 1.909
03/06/2018
04/17/2017
Dividend USD 2.303
03/01/2017
04/11/2016
Dividend USD 1.766665
02/24/2016
04/14/2015
Dividend USD 2.259
03/02/2015
05/13/2014
Dividend USD 1.794
02/27/2014
04/01/2013
Dividend USD 2.057
02/26/2013
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Webull offers kinds of Novartis AG (ADR) stock information, including NYSE:NVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVS stock methods without spending real money on the virtual paper trading platform.